Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom.

Neurogen Corporation is a drug development company historically focusing on small-molecule drugs to improve the lives of patients suffering from psychiatric and neurological disorders with significant unmet medical need. Neurogen has conducted its drug development independently and, when advantageous, collaborated with world-class pharmaceutical companies to access additional resources and expertise.

NTG Nordic Transport Group A/S is an international forwarding and logistics provider for road freight, sea freight, air freight and contract logistics. It operates through two segments: Road & Logistics and Air & Ocean. The Road & Logistics segment provides transport and warehousing solutions with a geographical focus on Europe. The Air & Ocean segment provides international air and ocean freight services, including project transports. The company was founded by Jørgen Buus Lassen in 1989 and is headquartered in Hvidovre, Denmark.

Ferrer Internacional SA engages in the development, manufacture and commercialization of pharmaceutical products for the diagnosis and treatment of cardiovascular, dermatological, gastrointestinal and respiratory conditions. It also designs and produces active ingredients and nutraceuticals for the food, cosmetics and animal feed industries. The company was founded on April 17, 1940 and is headquartered in Barcelona, Spain.

AgeneBio is a neuroscience pharmaceutical company founded by Dr Michela Gallagher in 2008 that is focused on developing treatments for diseases that impact memory. The initial therapeutic targets are Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD). The company is headquartered in Indianapolis but conducts research and development work on a global basis utilizing partner relationships.

Pfizer Ltd. is a biopharmaceutical company that develops and provides medicines, vaccines, and consumer healthcare products. Its products include prescription and counterfeit medicines, and over-the-counter products. The company was founded in 1952 and is headquartered in Tadworth, the United Kingdom.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Aniona ApS is a Danish private company located in Ballerup focused on offices and clinics of doctors of medicine. It was founded by Claus Tycho Br��strup, J��rgen Drejer, Thomas Feldthus and Anker Gunvald Lundemose. J��rgen Drejer is currently the CEO of the firm.

CoCensys, Inc. discovers and develops drugs to treat neurological and psychiatric disorders. The company's product development programs focus on two novel and proprietary classes of compounds: Epalons, to treat epilepsy, migraine, anxiety and sleep disorders and Excitatory Amino Acid (EAA) receptor antagonists, to treat stroke, head trauma, epilepsy and Parkinson's disease. The company was founded in 1989 and is located in Irvine, CA.

Saniona A/S, part of Saniona AB, is a Danish company. The firm engages in research and experimental development on natural sciences and engineering.

Helicon Therapeutics is a privately held Company formed to discover therapeutics to treat disorders of cognition through an understanding of the genetic basis of long-term memory formation. The scientific origin and founding intellectual property came from the neuroscience program at the Cold Spring Harbor Laboratory. Through seminal studies of learning and memory in fruit flies, a key function of the CREB (cAMP Response Element Binding Protein) gene was defined for the first time. The CREB gene encodes a protein which regulates the biochemical pathway that converts short-term memory to long-term memory - and it appears to function similarly in both fruit fly and in man. Further functional genomic studies have identified a large number of additional genes that participate in this (and parallel) memory pathway(s). All of these genes are potential targets for the production of drugs that enhance or diminish memory formation.

Uwm Research Foundation, Inc. is an American private company located in Milwaukee, WI. The firm operates as a research foundation.

Part of Akzo Nobel NV, Interquim SA is a Colombian company. The firm manufactures plant extracts and intermediates.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Neurocycle Therapeutics is a biopharmaceutical company that focuses on sub-type selective GABA-A modulation. By selectively targeting a newly-identified mechanism of action, their lead candidate (NCT10004) effectively reduced itch to near-baseline levels across a broad range of models including allergic and contact dermatitis models. Their selective compounds also produced significant relief of chronic pain in multiple studies and showed excellent efficacy in models of epilepsy. These compounds act quickly, do not suppress the immune system, show no signs of dependency/addiction, and do not lose efficacy over time. Their objective is to deliver next-generation treatments for the itch, pain, and certain refractory forms of pediatric epilepsy that are superior or complementary to existing treatments.